NOVEN TO PRESENT AT AT UBS GLOBAL LIFE SCIENCES CONFERENCE |
BackMiami, FL, September
20, 2007 -- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) ) today announced
that Robert Strauss, Noven’s President, CEO & Chairman, is
scheduled to provide an update on Noven’s business and prospects
at the UBS Global Life Sciences Conference in New York City on Tuesday,
September 25th at 8:00 a.m. ET. The public is invited to listen to
the presentation live via webcast at www.noven.com, and a replay will
be available for at least two weeks at the same site.
About
Noven
Noven Pharmaceuticals,
Inc., headquartered in Miami, Florida, has established itself as a leading
developer of advanced transdermal drug delivery technologies and prescription
transdermal products. Its commercialized transdermal products include Vivelle-Dot® (estradiol
transdermal system), the most prescribed estrogen patch in the U.S.,
and Daytrana™ (methylphenidate transdermal system), the first and
only patch approved for the treatment of ADHD.
With the acquisition of JDS Pharmaceuticals in August 2007, Noven has
become a broader-based specialty pharmaceutical company with the infrastructure,
products and category expertise to market and sell products itself, and
with a substantially enhanced late-stage product pipeline.
See www.noven.com
for additional information.
Contact:
|
Copyright © 2007 Noven Pharmaceuticals, Inc. All rights reserved.